RxDoctor Payments Data

Vinod Patel, MD

Interventional Cardiology · Brooklyn, NYNPI 1609814490

Payments from drug & device makers

$37,375in general payments, 2019–2025

Across 931 payments — averaging $40.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Scpharmaceuticals Inc.$7K
  • Abbott$5K
  • Cvrx, Inc.$3K
  • Medtronic$2K
  • Novo Nordisk$2K
  • Boston Scientific$2K
  • plus $16K from 54 others

What the payments were for

  • Consulting fees$210%
  • Speaking & faculty fees$6,00016%
  • Travel & lodging$8702%
  • Food & beverage$30,32981%
  • Education$1550%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Scpharmaceuticals Inc.18$6,885
Abbott86$4,673
Cvrx, Inc.32$2,939
Medtronic(2 entities)33$2,292
Novo Nordisk94$2,135
Boston Scientific38$2,028
Johnson & Johnson(2 entities)64$1,907
AstraZeneca73$1,536
Bardy Diagnostics, Inc.16$1,283
Boehringer Ingelheim52$1,110
Novartis64$1,097
Lilly USA, LLC55$1,090
Kestra Medical Technology Services, Inc.16$1,021
Amgen48$991
Cardiovascular Systems Inc.17$565
Pfizer30$527
Exact Sciences13$475
Biotronik Inc.9$473
Merck22$384
E.r. Squibb & Sons, L.L.C.19$357
Abiomed2$302
Esperion Therapeutics, Inc.7$258
Alnylam Pharmaceuticals Inc.11$253
Sanofi-aventis U.S. LLC14$242
Corcept Therapeutics8$203
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC11$183
Recor Medical Inc1$172
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)4$168
Stryker1$140
Lexicon Pharmaceuticals, Inc.6$137
Actelion Pharmaceuticals US, Inc.3$129
Intra-sana Laboratories6$127
Phathom Pharmaceuticals, Inc.1$125
Amarin Pharma, Inc.7$111
Shockwave Medical, Inc1$98
Gilead6$95
GSK4$85
Bayer4$82
Heartflow, Inc.4$80
Bridgebio Pharma, Inc.3$73
Preventice Services, LLC2$65
Agepha Pharma FZ LLC2$50
Dexcom, Inc.2$39
Smith+Nephew2$31
Vifor Pharma, Inc.2$31
Kowa Pharmaceuticals America, Inc.2$28
Medicomp Inc1$28
Philips North America LLC1$26
Vivaquant Inc, Dba Rhythm Express1$22
Baxter Healthcare1$21
Tactile Systems Technology Inc1$21
Coala Life Inc1$21
Edwards Lifesciences1$19
Terumo Medical Corporation1$19
Althera Pharmaceuticals LLC1$18
Glycomark, Inc.1$17
Cequr Corporation1$16
Atricure, Inc.1$16
Lundbeck LLC1$14
Mannkind Corporation1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$37,375 in reported general payments places this provider in the 70th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$1,189,217
Medicare patients
650
Services billed
7,161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin545$594,340
OzempicSemaglutide198$277,369
EliquisApixaban200$187,711
MounjaroTirzepatide117$174,495
EntrestoSacubitril/Valsartan128$148,630
JanumetSitagliptin Phos/Metformin Hcl114$145,282
FarxigaDapagliflozin Propanediol147$122,828
XareltoRivaroxaban132$106,007
FuroscixFurosemide13$93,819
JanuviaSitagliptin Phosphate39$45,723
TrulicityDulaglutide38$39,878
SynjardyEmpagliflozin/Metformin Hcl33$37,371
LinzessLinaclotide27$29,754
BrilintaTicagrelor24$21,177
Repatha PushtronexEvolocumab23$21,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Synjardy$1,110$631,711578 claims
Novo NordiskOzempic$2,135$277,369198 claims
Lilly USA, LLCMounjaro, Trulicity$1,090$214,374155 claims
MerckJanumet, Januvia$384$191,005153 claims
PfizerEliquis$527$187,711200 claims
AstraZenecaFarxiga, Brilinta, Lokelma$1,536$163,291187 claims
NovartisEntresto$1,097$148,630128 claims
Johnson & JohnsonXarelto$1,907$106,007132 claims
Scpharmaceuticals Inc.Furoscix$6,885$93,81913 claims
GSKBreo Ellipta, Arnuity Ellipta$85$11,87535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 382 interventional cardiology providers in New York.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →